… Open label and non-placebo controlled trials on tetrabenazine and the RCT included in this
meta-analysis support the efficacy of this medication class in TD.69,98 VMAT2 inhibitors are …

T ardive dyskinesia (TD), a neurologic disorder of involuntary movements, most commonly
occurs in 15%-30% of patients taking antipsychotic drugs for many years; however, in some …

… The majority of these studies used an 8- to 12-week intervention based on ethyl-eicosapentaenoic
acid. A randomized placebo-controlled trial was designed to compare the efficacy of …

… , randomized, double-blind placebo controlled trials in the TD population [29,30]. The ARM-TD
study … or probably ineffective include diltiazem, eicosapentaenoic acid, and galantamine. …

… ie, eicosapentaenoic acid, EPA; docosapentaenoic acid, DPA and docosahexaenoic acid,
DHA) and omega-6 (ie, arachidonic acid, … randomized placebo controlled 16-week clinical trial …

… Non-random lorazepam assignment raises two possibilities for interpreting our finding of
substantial effects with participants who did not receive lorazepam but not with those who did …

… double-blind, randomized, placebo controlled trials [27,28,72]. Two long-term retrospective
… in a meta-analysis of 3 randomized, placebo-controlled clinical trials of EGb-761 (Gingko …

… A randomized, doubleblind, placebo-controlled trial of deutetrabenazine for the treatment
of tardive dyskinesia (ARM-TD). Poster presented at: The American Psychiatric Association …

… randomized clinical trials assessing efficacy of different drug regimens in managing tardive
dyskinesia … , double-blind, placebo-controlled study. Mov Disord Off J Mov Disord Soc 30(12):…

… acids containing eicosapentaenoic acid >1 g/d showed significant improvement. A favorable
effect of omega-3 polyunsaturated fatty acids … 60 years; with tardive dyskinesia; unspecified; …